Suppr超能文献

慢性手部湿疹的管理:回顾性患者病历回顾。

The management of Chronic Hand Eczema: A retrospective patient record review.

机构信息

LEO Pharma A/S, Ballerup, Denmark.

Lumanity, London, UK.

出版信息

Contact Dermatitis. 2024 Apr;90(4):365-371. doi: 10.1111/cod.14477. Epub 2024 Jan 1.

Abstract

BACKGROUND

Chronic Hand Eczema (CHE) is a heterogeneous fluctuating inflammatory disease that represents a significant burden. Effective treatment options for moderate to severe CHE are limited.

OBJECTIVES

To assess how patients with moderate to severe CHE are treated in clinical practice.

METHODS

A retrospective, physician-led patient record review assessed the demographic, clinical and treatment characteristics of patients aged ≥18 years with CHE across seven countries. Each participating physician was requested to review records for their three most recent patients with moderate to severe CHE treated with a topical or systemic therapy.

RESULTS

A total of 264 physicians, of whom 88.6% were dermatologists and 70.1% were predominantly or partly hospital-based, reviewed the records of 792 patients. Signs were present on hands only in 56.4% of patients and the mean time on current treatment was 16.7 months. Overall, 62.9% of patients received systemic therapy and almost one-quarter (23.4%) were treated with a biologic; 28.6% of patients were only treated with topical corticosteroids and/or topical calcineurin inhibitors.

CONCLUSION

In patients with moderate to severe CHE, most received systemic therapy with one-quarter on biologic therapy. However, given that many of these treatments have limited evidence of efficacy in CHE, there is a need for studies specifically in patients with CHE as well as new therapeutic options.

摘要

背景

慢性手部湿疹(CHE)是一种异质性波动的炎症性疾病,给患者带来了沉重的负担。对于中重度 CHE,有效的治疗选择有限。

目的

评估中重度 CHE 患者在临床实践中的治疗情况。

方法

回顾性、医生主导的患者病历回顾评估了七个国家中年龄≥18 岁的中重度 CHE 患者的人口统计学、临床和治疗特征。每位参与的医生被要求回顾其最近治疗的三位中重度 CHE 患者的病历,这些患者接受了局部或全身治疗。

结果

共有 264 名医生参与了回顾,其中 88.6%为皮肤科医生,70.1%主要或部分为医院医生。这些医生回顾了 792 名患者的病历。仅手部有症状的患者占 56.4%,目前治疗的平均时间为 16.7 个月。总体而言,62.9%的患者接受了全身治疗,近四分之一(23.4%)接受了生物制剂治疗;28.6%的患者仅接受了局部皮质类固醇和/或局部钙调神经磷酸酶抑制剂治疗。

结论

在中重度 CHE 患者中,大多数患者接受了全身治疗,其中四分之一接受了生物制剂治疗。然而,鉴于这些治疗方法在 CHE 中的疗效证据有限,仍需要针对 CHE 患者进行专门的研究,并寻求新的治疗选择。

相似文献

1
The management of Chronic Hand Eczema: A retrospective patient record review.
Contact Dermatitis. 2024 Apr;90(4):365-371. doi: 10.1111/cod.14477. Epub 2024 Jan 1.
3
Hand eczema and steroid-refractory chronic hand eczema in general practice: prevalence and initial treatment.
Br J Dermatol. 2017 Apr;176(4):955-964. doi: 10.1111/bjd.14974. Epub 2017 Mar 8.
4
Current and emerging therapies for hand eczema.
Dermatol Ther. 2019 May;32(3):e12840. doi: 10.1111/dth.12840. Epub 2019 Feb 18.
5
Everyday clinical experience of alitretinoin in the treatment of severe chronic hand eczema: seven case studies.
Clin Exp Dermatol. 2011 Mar;36 Suppl:1-2. doi: 10.1111/j.1365-2230.2010.04006_1.x.
6
Efficacy of alitretinoin depending on the concomitant use of topical corticosteroids in chronic hand eczema patients.
J Dermatol. 2019 Nov;46(11):998-1005. doi: 10.1111/1346-8138.15071. Epub 2019 Sep 18.
8
Current emerging and investigational drugs for the treatment of chronic hand eczema.
Expert Opin Investig Drugs. 2022 Aug;31(8):843-853. doi: 10.1080/13543784.2022.2087059. Epub 2022 Jun 17.
9
Chronic hand eczema in Germany: 5-year follow-up data from the CARPE registry.
Contact Dermatitis. 2019 Jan;80(1):45-53. doi: 10.1111/cod.13113. Epub 2018 Sep 24.
10
Impact of systemic alitretinoin treatment on skin barrier gene and protein expression in patients with chronic hand eczema.
Br J Dermatol. 2016 Dec;175(6):1243-1250. doi: 10.1111/bjd.14921. Epub 2016 Oct 7.

引用本文的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验